Advanced search options

Advanced Search Options 🞨

Browse by author name (“Author name starts with…”).

Find ETDs with:

in
/  
in
/  
in
/  
in

Written in Published in Earliest date Latest date

Sorted by

Results per page:

Sorted by: relevance · author · university · dateNew search

You searched for +publisher:"University of Cincinnati" +contributor:("Desai, Pankaj"). Showing records 1 – 7 of 7 total matches.

Search Limiters

Last 2 Years | English Only

No search limiters apply to these results.

▼ Search Limiters


University of Cincinnati

1. Moorthy, Ganesh. Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment.

Degree: PhD, Pharmacy: Pharmaceutical Sciences/Biopharmaceutics, 2015, University of Cincinnati

 Dysregulation of PI3K/Akt/mTOR pathway has been implicated in tumorigenesis and malignancy in numerous solid tumors. Everolimus is a potent allosteric inhibitor of mTORC1, and has… (more)

Subjects/Keywords: Pharmaceuticals; pharmacokinetics; Phase I; PBPK; DDI; BEZ235; Everolimus

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Moorthy, G. (2015). Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment. (Doctoral Dissertation). University of Cincinnati. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=ucin1439296033

Chicago Manual of Style (16th Edition):

Moorthy, Ganesh. “Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment.” 2015. Doctoral Dissertation, University of Cincinnati. Accessed April 11, 2021. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1439296033.

MLA Handbook (7th Edition):

Moorthy, Ganesh. “Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment.” 2015. Web. 11 Apr 2021.

Vancouver:

Moorthy G. Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment. [Internet] [Doctoral dissertation]. University of Cincinnati; 2015. [cited 2021 Apr 11]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1439296033.

Council of Science Editors:

Moorthy G. Clinical Pharmacokinetics of the Novel Combination of BEZ235, PI3K/mTOR Inhibitor, and Everolimus, mTOR Inhibitor: Phase I Clinical Studies and Non-clinical Mechanistic Assessment. [Doctoral Dissertation]. University of Cincinnati; 2015. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1439296033


University of Cincinnati

2. Bhongsatiern, Jiraganya (JJ). Population Pharmacokinetics and Dosing Recommendations of Vancomycin in Neonates Using Modeling and Simulation Approach.

Degree: PhD, Pharmacy: Pharmaceutical Sciences/Biopharmaceutics, 2015, University of Cincinnati

 Sources of variability in drug exposure play an important role in evidence-based drug dosing strategies. Body size representing growth and age representing developmental changes are… (more)

Subjects/Keywords: Pharmaceuticals; population pharmacokinetics; infectious diseases; special populations; neonates; vancomycin; dosing strategy

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Bhongsatiern, J. (. (2015). Population Pharmacokinetics and Dosing Recommendations of Vancomycin in Neonates Using Modeling and Simulation Approach. (Doctoral Dissertation). University of Cincinnati. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=ucin1447689427

Chicago Manual of Style (16th Edition):

Bhongsatiern, Jiraganya (JJ). “Population Pharmacokinetics and Dosing Recommendations of Vancomycin in Neonates Using Modeling and Simulation Approach.” 2015. Doctoral Dissertation, University of Cincinnati. Accessed April 11, 2021. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1447689427.

MLA Handbook (7th Edition):

Bhongsatiern, Jiraganya (JJ). “Population Pharmacokinetics and Dosing Recommendations of Vancomycin in Neonates Using Modeling and Simulation Approach.” 2015. Web. 11 Apr 2021.

Vancouver:

Bhongsatiern J(. Population Pharmacokinetics and Dosing Recommendations of Vancomycin in Neonates Using Modeling and Simulation Approach. [Internet] [Doctoral dissertation]. University of Cincinnati; 2015. [cited 2021 Apr 11]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1447689427.

Council of Science Editors:

Bhongsatiern J(. Population Pharmacokinetics and Dosing Recommendations of Vancomycin in Neonates Using Modeling and Simulation Approach. [Doctoral Dissertation]. University of Cincinnati; 2015. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1447689427


University of Cincinnati

3. Dave, Nimita D. Brain/Brain Tumor Pharmacokinetics and Pharmacodynamics of Letrozole.

Degree: PhD, Pharmacy: Pharmaceutical Sciences/Biopharmaceutics, 2013, University of Cincinnati

 The lack of well-identified targets and limited access of drugs across the blood-brain and blood- tumor barriers are major impediments to the treatment of brain… (more)

Subjects/Keywords: Pharmaceuticals; pharmacokinetics; pharmacodynamics; letrozole; brain tumor; preclinical; glioma

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Dave, N. D. (2013). Brain/Brain Tumor Pharmacokinetics and Pharmacodynamics of Letrozole. (Doctoral Dissertation). University of Cincinnati. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=ucin1368013158

Chicago Manual of Style (16th Edition):

Dave, Nimita D. “Brain/Brain Tumor Pharmacokinetics and Pharmacodynamics of Letrozole.” 2013. Doctoral Dissertation, University of Cincinnati. Accessed April 11, 2021. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1368013158.

MLA Handbook (7th Edition):

Dave, Nimita D. “Brain/Brain Tumor Pharmacokinetics and Pharmacodynamics of Letrozole.” 2013. Web. 11 Apr 2021.

Vancouver:

Dave ND. Brain/Brain Tumor Pharmacokinetics and Pharmacodynamics of Letrozole. [Internet] [Doctoral dissertation]. University of Cincinnati; 2013. [cited 2021 Apr 11]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1368013158.

Council of Science Editors:

Dave ND. Brain/Brain Tumor Pharmacokinetics and Pharmacodynamics of Letrozole. [Doctoral Dissertation]. University of Cincinnati; 2013. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1368013158

4. Ananthula, Hari Krishna. Pharmacokinetic Evaluation and Modeling of Tyrosine Kinase Inhibitors Nilotinib and Imatinib in Preclinical Species to Aid their Repurposing As Anti-Viral Agents.

Degree: PhD, Pharmacy: Pharmaceutical Sciences/Biopharmaceutics, 2017, University of Cincinnati

 Tyrosine kinase inhibitors (TKIs) imatinib and nilotinib developed as anti-cancer drugs, also appear to have anti-viral activity due to their ability to disrupt productive replication… (more)

Subjects/Keywords: Pharmaceuticals; Tyrosine kinase inhibitor; Pharmacokinetics; Animal rule; Allometry; PBPK

…the College of Pharmacy and the University of Cincinnati for providing me the opportunity… 

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Ananthula, H. K. (2017). Pharmacokinetic Evaluation and Modeling of Tyrosine Kinase Inhibitors Nilotinib and Imatinib in Preclinical Species to Aid their Repurposing As Anti-Viral Agents. (Doctoral Dissertation). University of Cincinnati. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=ucin1504802233495176

Chicago Manual of Style (16th Edition):

Ananthula, Hari Krishna. “Pharmacokinetic Evaluation and Modeling of Tyrosine Kinase Inhibitors Nilotinib and Imatinib in Preclinical Species to Aid their Repurposing As Anti-Viral Agents.” 2017. Doctoral Dissertation, University of Cincinnati. Accessed April 11, 2021. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1504802233495176.

MLA Handbook (7th Edition):

Ananthula, Hari Krishna. “Pharmacokinetic Evaluation and Modeling of Tyrosine Kinase Inhibitors Nilotinib and Imatinib in Preclinical Species to Aid their Repurposing As Anti-Viral Agents.” 2017. Web. 11 Apr 2021.

Vancouver:

Ananthula HK. Pharmacokinetic Evaluation and Modeling of Tyrosine Kinase Inhibitors Nilotinib and Imatinib in Preclinical Species to Aid their Repurposing As Anti-Viral Agents. [Internet] [Doctoral dissertation]. University of Cincinnati; 2017. [cited 2021 Apr 11]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1504802233495176.

Council of Science Editors:

Ananthula HK. Pharmacokinetic Evaluation and Modeling of Tyrosine Kinase Inhibitors Nilotinib and Imatinib in Preclinical Species to Aid their Repurposing As Anti-Viral Agents. [Doctoral Dissertation]. University of Cincinnati; 2017. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1504802233495176


University of Cincinnati

5. Samineni, Divya. Pre-Clinical and Clinical Investigation of Pharmacokinetic and Pharmacodynamic Interactions between Darunavir, a Novel Protease Inhibitor and Rosuvastatin.

Degree: PhD, Pharmacy: Pharmaceutical Sciences/Biopharmaceutics, 2011, University of Cincinnati

  Treatment of dyslipidemia in HIV-infected persons is commonly required with the use of protease inhibitors (PIs) which may be restricted by drug-drug interactions between… (more)

Subjects/Keywords: Pharmaceuticals; Pharmacokinetics; Pharmacodynamics; Pharmacogenomics; Rosuvastatin; Darunavir; OATP1B1 Uptake

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Samineni, D. (2011). Pre-Clinical and Clinical Investigation of Pharmacokinetic and Pharmacodynamic Interactions between Darunavir, a Novel Protease Inhibitor and Rosuvastatin. (Doctoral Dissertation). University of Cincinnati. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=ucin1314040722

Chicago Manual of Style (16th Edition):

Samineni, Divya. “Pre-Clinical and Clinical Investigation of Pharmacokinetic and Pharmacodynamic Interactions between Darunavir, a Novel Protease Inhibitor and Rosuvastatin.” 2011. Doctoral Dissertation, University of Cincinnati. Accessed April 11, 2021. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1314040722.

MLA Handbook (7th Edition):

Samineni, Divya. “Pre-Clinical and Clinical Investigation of Pharmacokinetic and Pharmacodynamic Interactions between Darunavir, a Novel Protease Inhibitor and Rosuvastatin.” 2011. Web. 11 Apr 2021.

Vancouver:

Samineni D. Pre-Clinical and Clinical Investigation of Pharmacokinetic and Pharmacodynamic Interactions between Darunavir, a Novel Protease Inhibitor and Rosuvastatin. [Internet] [Doctoral dissertation]. University of Cincinnati; 2011. [cited 2021 Apr 11]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1314040722.

Council of Science Editors:

Samineni D. Pre-Clinical and Clinical Investigation of Pharmacokinetic and Pharmacodynamic Interactions between Darunavir, a Novel Protease Inhibitor and Rosuvastatin. [Doctoral Dissertation]. University of Cincinnati; 2011. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1314040722


University of Cincinnati

6. Mugundu, Ganesh. Pharmacogenetic Impact on Metabolism and Cytochrome P450 (CYP)3A Inductive Effect of Tamoxifen.

Degree: PhD, Pharmacy : Pharmaceutical Sciences, 2009, University of Cincinnati

  Tamoxifen (TAM) is an effective selective estrogen receptor modulator (SERM) widely used for the treatment and chemoprevention of estrogen receptor (ER) positive tumors. Notwithstanding… (more)

Subjects/Keywords: Pharmacology; Tamoxifen; Pharmacogenetics; CYP3A; Induction; Pharmacokinetics; Breast Cancer

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

Mugundu, G. (2009). Pharmacogenetic Impact on Metabolism and Cytochrome P450 (CYP)3A Inductive Effect of Tamoxifen. (Doctoral Dissertation). University of Cincinnati. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=ucin1266596002

Chicago Manual of Style (16th Edition):

Mugundu, Ganesh. “Pharmacogenetic Impact on Metabolism and Cytochrome P450 (CYP)3A Inductive Effect of Tamoxifen.” 2009. Doctoral Dissertation, University of Cincinnati. Accessed April 11, 2021. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1266596002.

MLA Handbook (7th Edition):

Mugundu, Ganesh. “Pharmacogenetic Impact on Metabolism and Cytochrome P450 (CYP)3A Inductive Effect of Tamoxifen.” 2009. Web. 11 Apr 2021.

Vancouver:

Mugundu G. Pharmacogenetic Impact on Metabolism and Cytochrome P450 (CYP)3A Inductive Effect of Tamoxifen. [Internet] [Doctoral dissertation]. University of Cincinnati; 2009. [cited 2021 Apr 11]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1266596002.

Council of Science Editors:

Mugundu G. Pharmacogenetic Impact on Metabolism and Cytochrome P450 (CYP)3A Inductive Effect of Tamoxifen. [Doctoral Dissertation]. University of Cincinnati; 2009. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1266596002


University of Cincinnati

7. SHROFF, PURVI B. AN ASSESSMENT OF THE POTENTIAL INFLUENCE OF BEXAROTENE, A NOVEL RETINOID X RECEPTOR AGONIST, ON THE HEPATIC METABOLISM OF BEXAROTENE.

Degree: MS, Pharmacy : Pharmaceutical Sciences, 2005, University of Cincinnati

 Background: Bexarotene, a novel RXR agonist, is used in the treatment of cutaneous T cell lymphoma and is under investigation for the treatment of solid… (more)

Subjects/Keywords: Biology, Molecular; Drug Interaction; Anti-cancer Drugs

Record DetailsSimilar RecordsGoogle PlusoneFacebookTwitterCiteULikeMendeleyreddit

APA · Chicago · MLA · Vancouver · CSE | Export to Zotero / EndNote / Reference Manager

APA (6th Edition):

SHROFF, P. B. (2005). AN ASSESSMENT OF THE POTENTIAL INFLUENCE OF BEXAROTENE, A NOVEL RETINOID X RECEPTOR AGONIST, ON THE HEPATIC METABOLISM OF BEXAROTENE. (Masters Thesis). University of Cincinnati. Retrieved from http://rave.ohiolink.edu/etdc/view?acc_num=ucin1123813553

Chicago Manual of Style (16th Edition):

SHROFF, PURVI B. “AN ASSESSMENT OF THE POTENTIAL INFLUENCE OF BEXAROTENE, A NOVEL RETINOID X RECEPTOR AGONIST, ON THE HEPATIC METABOLISM OF BEXAROTENE.” 2005. Masters Thesis, University of Cincinnati. Accessed April 11, 2021. http://rave.ohiolink.edu/etdc/view?acc_num=ucin1123813553.

MLA Handbook (7th Edition):

SHROFF, PURVI B. “AN ASSESSMENT OF THE POTENTIAL INFLUENCE OF BEXAROTENE, A NOVEL RETINOID X RECEPTOR AGONIST, ON THE HEPATIC METABOLISM OF BEXAROTENE.” 2005. Web. 11 Apr 2021.

Vancouver:

SHROFF PB. AN ASSESSMENT OF THE POTENTIAL INFLUENCE OF BEXAROTENE, A NOVEL RETINOID X RECEPTOR AGONIST, ON THE HEPATIC METABOLISM OF BEXAROTENE. [Internet] [Masters thesis]. University of Cincinnati; 2005. [cited 2021 Apr 11]. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1123813553.

Council of Science Editors:

SHROFF PB. AN ASSESSMENT OF THE POTENTIAL INFLUENCE OF BEXAROTENE, A NOVEL RETINOID X RECEPTOR AGONIST, ON THE HEPATIC METABOLISM OF BEXAROTENE. [Masters Thesis]. University of Cincinnati; 2005. Available from: http://rave.ohiolink.edu/etdc/view?acc_num=ucin1123813553

.